ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

Senate Appropriators Reject President’s $228 Million Increase For Cancer Research; House and Senate Report Language

September 18, 2009

FDA Publishes Parallel Track Rules, Accelerated Drug Approval Initiative

April 25, 1992

White House Says Upton Appointment Due In Two Weeks

July 29, 1977

CCOP RFA Due In Mid-July; DCT Board Gives Its Concept Approval

June 11, 1982

Text Of Working Group’s Recommendations

May 19, 1995

Varmus To Cut Five Percent From Cancer Centers As NCI Adjusts To “Financial disaster”

May 6, 2011